Department of Infectious Diseases, Zhongshan Hospital of Xiamen University, Xiamen, Fujian Province, People's Republic of China.
Main Examination Room, Xiamen Huli Guoyu Clinic, Co., Ltd., Xiamen, Fujian Province, People's Republic of China.
Medicine (Baltimore). 2021 Jul 30;100(30):e26641. doi: 10.1097/MD.0000000000026641.
This review aims to evaluate the supportive effects of frequently used traditional Chinese medicine (TCM) for the treatment of coronavirus disease 2019 (COVID-19).
Five databases were searched through July 7, 2020. Randomized controlled trials investigating the efficacy of TCM for use in the treatment of COVID-19 were included. Newcastle-Ottawa Scale (NOS) and modified Jadad score were used for the evaluation of the methodological quality of the included studies. Weighted mean difference, odds ratio (OR), and 95% confidence interval (95% CI) were calculated for pooling out results. Data were extracted for conducting a meta-analysis using STATA version 12.0.
Eight studies with a total of 750 patients were included in this meta-analysis. All included trial groups involved treatment with TCM and Western medicine, while the control groups were treated only with Western medicine. The intervention therapy significantly improved the overall effective rate (n = 346, OR = 2.5, 95% CIs = 1.46-4.29), fever symptom disappearance rate (n = 436; OR = 3.6; 95% CIs = 2.13-6.08), fatigue symptom disappearance rate (n = 436; OR = 3.04; 95% CIs = 1.76-5.26), cough symptom disappearance rate (n = 436; OR = 2.91; 95% CIs = 1.36-6.19), and sputum production reduction (n = 436; OR = 5.51; 95% CIs = 1.94-15.64). Based on the Newcastle-Ottawa Scale assessment, 6 studies received a score of 4, and 1 study achieved a score of 5. One study was assessed using the modified Jadad score, achieving a score of 6.
The integration of TCM with Western medicine has significantly improved the treatment for COVID-19 patients compared to Western medicine treatment alone. Combined therapy using TCM and Western medicine revealed the potential adjunctive role of TCM in treating COVID-19. However, high-quality clinical studies are still required to further evaluate the efficacy and safety of TCM in the treatment of COVID-19.
本综述旨在评估常用于治疗 2019 年冠状病毒病（COVID-19）的中药（TCM）的支持作用。
检索了五个数据库，检索时间截至 2020 年 7 月 7 日。纳入了使用 TCM 治疗 COVID-19 的疗效的随机对照试验。使用纽卡斯尔-渥太华量表（NOS）和改良 Jadad 量表对纳入研究的方法学质量进行评估。使用 STATA 版本 12.0 对汇总结果进行加权均数差、比值比（OR）和 95%置信区间（95%CI）计算。
纳入了 8 项共 750 例患者的研究进行了荟萃分析。所有纳入的试验组均接受 TCM 和西药治疗，而对照组仅接受西药治疗。干预疗法显著提高了总有效率（n=346，OR=2.5，95%CI=1.46-4.29）、退热症状消失率（n=436；OR=3.6；95%CI=2.13-6.08）、乏力症状消失率（n=436；OR=3.04；95%CI=1.76-5.26）、咳嗽症状消失率（n=436；OR=2.91；95%CI=1.36-6.19）和痰量减少率（n=436；OR=5.51；95%CI=1.94-15.64）。根据纽卡斯尔-渥太华量表评估，6 项研究评分为 4 分，1 项研究评分为 5 分。1 项研究使用改良 Jadad 量表评分，评分为 6 分。
与单独使用西药相比，TCM 与西药联合应用显著改善了 COVID-19 患者的治疗效果。TCM 与西药联合治疗显示了 TCM 在治疗 COVID-19 中的潜在辅助作用。但是，仍然需要高质量的临床研究来进一步评估 TCM 在 COVID-19 治疗中的疗效和安全性。
